nach oben

Neurological Sciences

Erschienen in:

17.04.2023 | Review Article

Safety and efficacy of lithium in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis of randomized controlled trials

verfasst von: Abdullah Ashraf Hamad, Amir N. Attia, Nada Mostafa Al-dardery, Shrouk F Mohamed, Mostafa Meshref

Erschienen in: Neurological Sciences | Ausgabe 9/2023

Einloggen, um Zugang zu erhalten

Abstract

Objectives

This study provides a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating the safety and efficacy of lithium in amyotrophic lateral sclerosis (ALS) patients.

Methods

PubMed, Web of Science, Cochrane CENTRAL, Scopus, and Your Journals@Ovid were searched up to 9 December 2022. RCTs investigating lithium, either alone or with any supplement, in ALS patients were included. Meta-analysis was performed using RevMan and results are presented in forest plot.

Results

Four RCTs with 469 patients met the inclusion criteria and were included in our study. Lithium doses varied among the included studies and one study used a combined therapy of lithium with valproate. Meta-analysis showed no difference between lithium and placebo regarding severe adverse events (odds ratio = 1.13, 95% confidence interval: 0.73 to 1.75, P = 0.58). No significant differences were observed with regard to survival rate between the two groups (hazard ratio = 0.95, 95% confidence interval: 0.65 to 1.37, P = 0.77). There were also no significant differences between the two groups with regard to average changes of revised amyotrophic lateral sclerosis functional rating scale (P = 0.35) and forced vital capacity percentage predicted (P = 0.73). Subgroup analysis showed no significant differences regarding all investigated outcomes either for lithium alone or lithium with valproate.

Conclusion

Current evidence suggests a safety profile with no benefit of lithium for ALS. However, given the limited number of RCTs and the safety findings, we recommend further well-designed RCTs to investigate lithium and valproate in ALS patients.

Hardiman O, Al-Chalabi A, Chio A et al (2017) Amyotrophic lateral sclerosis [published correction appears in Nat Rev Dis Primers. 2017 Oct 20;3:17085]. Nat Rev Dis Primers 3:17071. Published 2017 Oct 5. https://doi.org/10.1038/nrdp.2017.71

Mehta P, Horton DK, Kasarskis EJ et al (2017) CDC Grand Rounds: National Amyotrophic Lateral Sclerosis (ALS) Registry Impact, Challenges, and Future Directions [published correction appears in MMWR Morb Mortal Wkly Rep. 2018 Jan 19;67(2):81]. MMWR Morb Mortal Wkly Rep 66(50):1379–1382. Published 2017 Dec 22. https://doi.org/10.15585/mmwr.mm6650a3

Bettencourt C, Houlden H (2015) Exome sequencing uncovers hidden pathways in familial and sporadic ALS. Nat Neurosci 18(5):611–613. https://doi.org/10.1038/nn.4012CrossRefPubMed

Brown CA, Lally C, Kupelian V, Flanders WD (2021) Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants. Neuroepidemiology 55(5):342–353. https://doi.org/10.1159/000516752CrossRefPubMed

Bensimon G, Lacomblez L, Meininger V (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 330(9):585–591. https://doi.org/10.1056/NEJM199403033300901

Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347(9013):1425–1431. https://doi.org/10.1016/s0140-6736(96)91680-3

Writing Group; Edaravone (MCI-186) ALS 19 Study Group (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7):505–512. https://doi.org/10.1016/S1474-4422(17)30115-1

Paganoni S, Macklin EA, Hendrix S et al (2020) Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. N Engl J Med 383(10):919–930. https://doi.org/10.1056/NEJMoa1916945CrossRefPubMedCentral

Nivoli AM, Colom F, Murru A et al (2011) New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 129(1–3):14–26. https://doi.org/10.1016/j.jad.2010.05.018CrossRefPubMed

10.

Pasquali L, Busceti CL, Fulceri F, Paparelli A, Fornai F (2010) Intracellular pathways underlying the effects of lithium. Behav Pharmacol 21(5–6):473–492. https://doi.org/10.1097/FBP.0b013e32833da5daCrossRefPubMed

11.

Won E, Kim YK (2017) An Oldie but Goodie: Lithium in the Treatment of Bipolar Disorder through Neuroprotective and Neurotrophic Mechanisms. Int J Mol Sci. 18(12):2679. Published 2017 Dec 11. https://doi.org/10.3390/ijms18122679

12.

Chalecka-Franaszek E, Chuang DM (1999) Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 96(15):8745–8750. https://doi.org/10.1073/pnas.96.15.8745CrossRefPubMedPubMedCentral

13.

Hashimoto R, Senatorov V, Kanai H, Leeds P, Chuang DM (2003) Lithium stimulates progenitor proliferation in cultured brain neurons. Neuroscience 117(1):55–61. https://doi.org/10.1016/s0306-4522(02)00577-8CrossRefPubMed

14.

Hashimoto R, Takei N, Shimazu K, Christ L, Lu B, Chuang DM (2002) Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology 43(7):1173–1179. https://doi.org/10.1016/s0028-3908(02)00217-4CrossRefPubMed

15.

Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM (2008) Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 155(3):567–572. https://doi.org/10.1016/j.neuroscience.2008.06.040CrossRefPubMed

16.

Dill J, Wang H, Zhou F, Li S (2008) Inactivation of glycogen synthase kinase 3 promotes axonal growth and recovery in the CNS. J Neurosci 28(36):8914–8928. https://doi.org/10.1523/JNEUROSCI.1178-08.2008CrossRefPubMedPubMedCentral

17.

Vallée A, Vallée JN, Lecarpentier Y (2021) Parkinson's Disease: Potential Actions of Lithium by Targeting the WNT/β-Catenin Pathway, Oxidative Stress, Inflammation and Glutamatergic Pathway. Cells 10(2):230. Published 2021 Jan 25. https://doi.org/10.3390/cells10020230

18.

Lazzara CA, Kim YH (2015) Potential application of lithium in Parkinson's and other neurodegenerative diseases. Front Neurosci 9:403. Published 2015 Oct 27. https://doi.org/10.3389/fnins.2015.00403

19.

Fornai F, Longone P, Cafaro L et al (2008) Lithium delays progression of amyotrophic lateral sclerosis [published correction appears in Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16404–7]. Proc Natl Acad Sci U S A 105(6):2052–2057. https://doi.org/10.1073/pnas.0708022105

20.

Aggarwal SP, Zinman L, Simpson E et al (2010) Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9(5):481–488. https://doi.org/10.1016/S1474-4422(10)70068-5CrossRefPubMedPubMedCentral

21.

Boll MC, Alcaraz-Zubeldia M, Rios C, González-Esquivel D, Montes S (2022) A phase 2, double-blind, placebo-controlled trial of a valproate/lithium combination in ALS patients [published online ahead of print, 2022 Aug 29]. Neurologia (Engl Ed) S2173–5808(22)00089-X. https://doi.org/10.1016/j.nrleng.2022.07.003

22.

Willemse SW, Roes KCB, Van Damme P et al (2022) Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial. Trials 23(1):978. https://doi.org/10.1186/s13063-022-06906-5CrossRefPubMedPubMedCentral

23.

Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535. Published 2009 Jul 21. https://doi.org/10.1136/bmj.b2535

24.

Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1(5):293–299. https://doi.org/10.1080/146608200300079536

25.

Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev 5(1):210. Published 2016 Dec 5. https://doi.org/10.1186/s13643-016-0384-4

26.

Altman DG, Bland JM (2011) How to obtain the confidence interval from a P value. BMJ 343:d2090. Published 2011 Aug 8. https://doi.org/10.1136/bmj.d2090

27.

Sterne JAC, Savović J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. Published 2019 Aug 28. https://doi.org/10.1136/bmj.l4898

28.

Verstraete E, Veldink JH, Huisman MH et al (2012) Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomised sequential trial. J Neurol Neurosurg Psychiatry 83(5):557–564. https://doi.org/10.1136/jnnp-2011-302021CrossRefPubMed

29.

UKMND-LiCALS Study Group, Morrison KE, Dhariwal S et al (2013) Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial [published correction appears in Lancet Neurol. 2013 Sep;12(9):846]. Lancet Neurol 12(4):339–345. https://doi.org/10.1016/S1474-4422(13)70037-1

30.

van Harten PN, Hoek HW, Matroos GE, van Os J (2008) Evidence that lithium protects against tardive dyskinesia: the Curaçao Extrapyramidal syndromes study VI. Eur Neuropsychopharmacol 18(2):152–155. https://doi.org/10.1016/j.euroneuro.2007.07.004CrossRefPubMed

31.

Straten G, Saur R, Laske C et al (2011) Influence of lithium treatment on GDNF serum and CSF concentrations in patients with early Alzheimer’s disease. Curr Alzheimer Res 8(8):853–859. https://doi.org/10.2174/156720511798192754CrossRefPubMed

32.

Berk M, Dandash O, Daglas R et al (2017) Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume [published correction appears in Transl Psychiatry. 2017 Feb 21;7(2):e1041]. Transl Psychiatry 7(1):e1011. https://doi.org/10.1038/tp.2016.281

33.

Miller RG, Moore DH, Forshew DA et al (2011) Phase II screening trial of lithium carbonate in amyotrophic lateral sclerosis: examining a more efficient trial design. Neurology 77(10):973–979. https://doi.org/10.1212/WNL.0b013e31822dc7a5CrossRefPubMedPubMedCentral

34.

Wicks P, Vaughan TE, Massagli MP, Heywood J (2011) Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nat Biotechnol 29(5):411–414. https://doi.org/10.1038/nbt.1837CrossRefPubMed

35.

Chiò A, Borghero G, Calvo A et al (2010) Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dose-finding trial. Neurology 75(7):619–625. https://doi.org/10.1212/WNL.0b013e3181ed9e7cCrossRefPubMed

36.

van Eijk RPA, Jones AR, Sproviero W et al (2017) Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials [published correction appears in Neurology. 2017 Nov 28;89(22):2303]. Neurology 89(18):1915–1922. https://doi.org/10.1212/WNL.0000000000004606

Titel: Safety and efficacy of lithium in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis of randomized controlled trials
verfasst von: Abdullah Ashraf Hamad
Amir N. Attia
Nada Mostafa Al-dardery
Shrouk F Mohamed
Mostafa Meshref
Publikationsdatum: 17.04.2023
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 9/2023
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-023-06814-9

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objectives

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2023

Assessment of the psychometric properties of the Italian version of the New Freezing of Gait Questionnaire (NFOG-Q-IT) in people with Parkinson disease: a validity and reliability study

Exploring depression in Parkinson’s disease: an Italian Delphi Consensus on phenomenology, diagnosis, and management

Hyperammonemic encephalopathy

Bringing door-to-needle times within the European benchmarks results in better stroke patients outcomes in a spoke hospital from the Apulian Region

FDXR-associated disease: a challenging differential diagnosis with inflammatory peripheral neuropathy